News | August 03, 2023
Narayana Hrudayalaya posts Q1 FY24 consolidated PAT at Rs. 183.95 Cr
The company has reported total income of Rs. 1248.51 crores during the period ended June 30, 2023
The company has reported total income of Rs. 1248.51 crores during the period ended June 30, 2023
Aims to foster a Resilient and Sustainable Healthcare Ecosystem
The company has reported total income of Rs. 135.87 crores during the period ended June 30, 2023
The company has reported total income of Rs. 164.63 crores during the period ended June 30, 2023
JDHL has a strong reputation as an end-to-end design-focused manufacturer of electro-medical devices
The company has secured 506 marketing approvals for its oncology products across 76 countries.
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
The company achieved 100% capacity utilisation in the division. These accomplishments stand as a testament to the company's dedication and vision
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy
The product basket increased to 1800 medicines and 285 Surgical Equipment
Subscribe To Our Newsletter & Stay Updated
